Hematology

North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.

A survivor shares axi-cel therapy highs, experiences with severe CRS and neurotoxicity, and why access to care and clinical trials improves QOL.

Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.

The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.

Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.

This new study from the VHA also shows neither cytoreductive therapy nor phlebotomy clearly lowers thrombosis risk.

Despite positive data, the study authors call for prospective validation before PRO burden is incorporated into broader risk-stratification approaches.

Community oncologists are steadily adopting bispecific antibodies for myeloma, but advance planning and tocilizumab remain key to safe access.

The PARADIGM trial excluded patients with NPM1 mutations, core binding factor alterations, and FLT-3–mutated disease, so the data should not apply to them.

Scheduling apheresis, manufacturing the cells, and ultimately administering the treatment can take several weeks, Madhav Seshadri, MD, explains.

Amandeep Godara, MBBS, explained that rural patients with multiple myeloma face various barriers to immunotherapies that may delay treatment.

Whether these findings will translate into a change in treatment guidelines remains to be seen.

Ropeginterferon alfa-2b-njft is expected to be available immediately.

Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.

Data show most older adults with newly diagnosed AML expect stable or improving physical function, while oncologists anticipate decline.

Selinexor, an oral XPO1 inhibitor, delivers modest spleen volume reduction in ruxolitinib-refractory MF with minimal myelosuppression in ESSENTIAL trial news.

FDA approves rusfertide, a first-in-class hepcidin-mimetic for polycythemia vera, cutting phlebotomies and improving hematocrit control and QOL.

Lymphomas arise from immune system cells and can create an environment less hospitable to CAR T-cell expansion, explained Kerry Rogers, MD.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally defined high-risk patients.

The study authors indicated that future investigations could further facilitate clinical decision-making regarding these regimens’ effectiveness.

For Xavier Leleu, MD, PhD, there is opportunity to ensure that therapeutic advances are accompanied by advances in how those therapies are delivered.

Institutions need to think more creatively about how they identify and elevate talent, explains Bhavana Bhatnagar, DO.

Lab abnormalities can emerge between visits, and pharmacists may be able to catch uncontrolled hematocrit, adherence issues, or access barriers early.